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The tumor suppressor p53 is important for inhibiting the development of breast carcinomas. However, little is known about the effects of
increased p53 activity on mammary gland development. Therefore, the effect of p53 dosage on mammary gland development was examined by
utilizing the p53+/m mouse, a p53 mutant which exhibits increased wild-type p53 activity, increased tumor resistance, a shortened longevity, and a
variety of accelerated aging phenotypes. Here we report that p53+/m virgin mice exhibit a defect in mammary gland ductal morphogenesis.
Transplants of mammary epithelium into p53+/m recipient mice demonstrate decreased outgrowth of wild-type and p53+/m donor epithelium,
suggesting systemic or stromal alterations in the p53+/m mouse. Supporting these data, p53+/m mice display decreased levels of serum IGF-1 and
reduced IGF-1 signaling in virgin glands. The induction of pregnancy or treatment of p53+/m mice with estrogen, progesterone, estrogen and
progesterone in combination, or IGF-1 stimulates ductal outgrowth, rescuing the p53+/m mammary phenotype. Serial mammary epithelium
transplants demonstrate that p53+/m epithelium exhibits decreased transplant capabilities, suggesting early stem cell exhaustion. These data
indicate that appropriate levels of p53 activity are important in regulating mammary gland ductal morphogenesis, in part through regulation of the
IGF-1 pathway.
© 2007 Elsevier Inc. All rights reserved.Keywords: p53; Mammary gland; Mouse; Ductal morphogenesis; IGF-1Introduction
In response to cellular stress, the tumor suppressor p53 plays
an important role in maintaining genome integrity and inhibiting
both cancer formation and progression by regulating the
expression of genes responsible for mediating DNA repair,
cell cycle arrest, apoptosis, and senescence (Bunz et al., 1998;
Chao et al., 2000; Vogelstein et al., 2000). Dysfunctional p53
signaling pathways or p53 mutations are present in over 80% of
all human cancers, including breast cancer (Lozano and Elledge,
2000). Proper function and regulation of p53 are important to⁎ Corresponding author. Baylor College of Medicine, Department of
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doi:10.1016/j.ydbio.2007.10.004prevent the development of human breast cancer, as mutations in
p53 are found in 30–40% of spontaneous breast carcinomas and
female Li–Fraumeni syndrome patients who carry a germline
mutation in one p53 allele have an increased incidence of early-
onset breast cancer (Akashi and Koeffler, 1998; Coles et al.,
1992; Moll et al., 1992). Further work to understand the role of
p53 in mammary gland development may provide insight into
mechanisms that regulate malignant transformation as well as
normal mammary epithelial cell growth.
The loss of p53 has been reported to have little effect on
mammary gland development, as p53 null mammary glands
were initially shown to be morphologically and functionally
comparable to wild-type glands (Donehower et al., 1992; Jacks
et al., 1994; Kuperwasser et al., 2000; Purdie et al., 1994).
However, loss of p53 in a BALB/c background causes a tran-
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mammary epithelium during early involution, where it mediates
apoptosis (Jerry et al., 1998). In the quiescent virgin gland, p53
mRNA levels are high in the mammary epithelium; however,
the virgin gland exhibits a decreased p53 response to DNA
damage, characterized by cytoplasmic sequestration of p53
(Kuperwasser et al., 2000; Minter et al., 2002). p53 activation is
highest during early and mid-pregnancy, correlating with an
increase in proliferation and steroid hormones (Becker et al.,
2005; Minter et al., 2002). Interestingly, treatment with
pregnancy-associated hormones allows nuclear accumulation
of p53 following irradiation in virgin glands (Kuperwasser et
al., 2000). Limited hormonal exposure of the mammary gland
during postpubertal development, through pregnancy or hor-
monal treatment, has a protective effect against breast cancer in
humans and rodents, which is dependent on the presence of
wild-type p53 (Medina and Kittrell, 2003). These studies show
that p53 activity is dependent upon hormonal status and varies
throughout development.
Recent studies have identified the ability of truncated forms
of p53 to enhance the activity of full-length wild-type p53,
including a mouse model developed in our laboratory, the
p53+/m mouse (Tyner et al., 2002). The p53+/m mice express
one wild-type p53 allele and a truncated C-terminal p53 mutant
allele, referred to as the “m” allele, which consists of p53 exons
7–11, with an Arg to Trp mutation at codon 245 (Tyner et al.,
2002). p53+/m mice are highly resistant to tumors, yet display a
reduction in median life span and exhibit a variety of accelerated
aging phenotypes (Tyner et al., 2002). The p53+/m mice also
exhibit alterations in hematopoietic stem cell (HSC) number,
proliferation, and engraftment capabilities with age, suggesting
that altered p53 levels affect stem cell functionality (Dumble
et al., 2007; Gatza et al., 2007). In response to γ-irradiation,
p53+/m tissues exhibit increased wild-type p53 protein levels,
indicating that the m protein can stabilize wild-type p53 (Tyner
et al., 2002; Moore et al., in press). The m allele also increases
the activity of wild-type p53, leading to increased transactivation
of the p53 target gene p21 and increased resistance to oncogenic
transformation in MEFs (Tyner et al., 2002). Although the m
protein is not a natural isoform of p53, it is similar to several
naturally occurring p53 isoforms, p44 andΔ133p53 (Bourdon et
al., 2005). In addition, the similarities between the p53+/m and
p44 mouse models indicate that the p53+/m mouse is biolo-
gically significant as a model of increased p53 activity (Maier
et al., 2004; Tyner et al., 2002).
Since p53 levels play an important role in protection against
mammary carcinogenesis, we investigated the effect of inc-
reased p53 activity on mammary gland development and stem
cell dynamics by utilizing the p53+/m mouse model. Mammary
gland stem cells are necessary for mammary gland development
and functionality, and alterations in stem cell proliferative
capabilities may lead to defects in the gland (Shackleton et al.,
2006; Stingl et al., 2006; Woodward et al., 2005). Additionally,
IGF-1, which plays a critical role in mediating mammary gland
development, has also been implicated in aging (Holzenberger
et al., 2003). p53 is known to transcriptionally repress ex-
pression of the IGF-1 receptor (IGF-1R) and transcriptionallyupregulate IGF-1 signaling inhibitors IGF-BP3 and PTEN,
demonstrating a direct role in p53-mediated regulation of the
IGF-1 pathway (Buckbinder et al., 1995; Stambolic et al., 2001;
Werner et al., 1996). Recently, several mouse models with
accelerated aging phenotypes have been shown to exhibit alter-
ations in IGF-1 signaling (Maier et al., 2004; Niedernhofer
et al., 2006; Shukla et al., 2006). Collectively, these studies
suggest that the p53+/m mouse may exhibit altered IGF-1
signaling, which could affect mammary gland development.
Here we report that p53+/m virgin mice exhibit a defect in
mammary gland ductal morphogenesis. Transplants of mam-
mary epithelium into p53+/m recipient mice demonstrate a
significant reduction of WT and p53+/m donor epithelium
outgrowth, suggesting systemic or stromal alterations in
p53+/m mice. In fact, p53+/m mice exhibit a decrease in
serum IGF-1 levels and attenuated IGF-1 signaling in the virgin
gland. The p53+/m mammary phenotype is rescued by
induction of pregnancy, treatment with estrogen, progesterone,
estrogen, and progesterone in combination, or LR3-IGF-1.
Collectively, these data demonstrate that alterations in p53




The mice used in this study were previously reported by our laboratory
(Donehower et al., 1992; Tyner et al., 2002), except the TTR-IGF-1mice (Liao et
al., 2006). p53 wild-type (WT) and p53+/m mice backcrossed seven generations
into C57BL/6 and p53+/− mice backcrossed 12 generations into C57BL/6 were
used for all experiments. The WT and p53+/m mice were generated by crossing
WT mice to p53+/m mice and were genotyped by PCR as previously described
(Dumble et al., 2007). p53+/− mice were produced by heterozygous crossings
and were genotyped by Southern Blot analysis as previously described
(Donehower et al., 1992). TTR-IGF-1 heterozygous mice were crossed to
BC7-p53+/m mice to generate TTR-IGF-1/+;p53+/m mice and were genotyped
by PCR as previously described (Dumble et al., 2007; Liao et al., 2006).
All mice were bred and maintained in a specific pathogen free animal facility
at Baylor College of Medicine. The 3-week-old C57BL/6 female recipient mice
used in the serial mammary epithelial transplantation experiments were pur-
chased from the Baylor College of Medicine Transgenic Mouse Barrier Facility.
Whole mount preparation
Mammary gland tissue was isolated and whole mounts were prepared as
previously described (Medina et al., 2002). The number four inguinal mammary
glands were harvested from WT, p53+/−, and p53+/m mice at 8 week virgin, 12
week virgin, 24 week virgin, mid-pregnancy (day 12), and D10 involution (10
days post weaning) and fixed in 10% neutral buffered formalin for at least 24 h.
Whole mounts were examined for ductal outgrowth under a dissecting
microscope (Olympus SZX12).
In vivo BrdU incorporation
Two hours prior to sacrifice, mice were treated with 7 mg/ml bromodeox-
yuridine (BrdU) cell proliferation reagent (Sigma Aldrich, St. Louis, MO, USA)
at 0.01 ml/gm of body weight. The number four inguinal mammary glands were
harvested fromWT, p53+/−, and p53+/m mice at 8 week virgin, 12 week virgin,
mid-pregnancy (day 12), and D10 involution and fixed in 4% paraformaldehyde
for 2 h followed by 70% ethanol. Fixed tissues were paraffin-embedded and
sectioned. Immunostaining for BrdU incorporation was performed using the
BrdU In-Situ Detection Kit (BD Pharmingen, San Diego, CA, USA). For each
132 C.E. Gatza et al. / Developmental Biology 313 (2008) 130–141sample, 500 ductal epithelial cells were counted over multiple fields and scored
as positive or negative for BrdU incorporation. The BrdU labeling index was
determined by calculating the average of the percent BrdU positive cells from
three separate glands.
TUNEL assay
The number four mammary glands were harvested from WT, p53+/−, and
p53+/m mice at 8 week virgin, 12 week virgin, mid-pregnancy (day 12), and
D10 involution and fixed in 4% paraformaldehyde for 2 h followed by 70%
ethanol. Fixed tissues were paraffin embedded and sectioned. Immunostaining
for apoptosis was performed using the In Situ Apoptosis Detection Kit
(Trevigen, Helgerman, CT, USA). For each sample, 500 cells were counted over
multiple fields and scored as TUNEL positive or negative. The percent apoptosis
was determined by calculating the average of the percent TUNEL positive cells
from three separate glands.
Serial mammary epithelial transplants
Serial mammary transplants were performed as previously described
(Medina et al., 2002). Briefly, the number four inguinal glands of five
3-week-old female WT C57BL/6 recipients were cleared by removal of the duct
containing fat pad below the primary lymph node and proximal to the nipple. A
1 mm2 piece of tissue from the number four mammary gland of an 8-week-old
female WT, p53+/−, or p53+/m donor mouse was transplanted into the cleared
glands of each of the five WT C57BL/6 recipients. Eight weeks post transplant,
the outgrowths were retransplanted into five WT recipients and the glands were
harvested, fixed in 4% paraformaldehyde for 2 h, transferred to 70% ethanol,
and then paraffin embedded or examined by whole mount. Serial transplants
were continued until the outgrowths failed to fill 10% of the mammary fat pad.
Mammary epithelium transplants into p53+/m recipients
The mammary glands of 3-week-old WT or p53+/m recipients were cleared
as previously described. Mammary epithelium from an 8-week WT donor was
transplanted into the left gland, while tissue from an 8-week p53+/m donor was
transplanted into the right mammary gland of each recipient mouse. Transplants
were harvested 4 weeks post transplant and whole mounted as previously
described. Examination of outgrowth was performed by blinded assessment of
whole mounts.
Hormone treatment
Ten to 12 week WT, p53+/−, and p53+/m virgin mice were subcutaneously
implanted in the sub-scapular region with Silastic brand capsules (Dow Corning,
Midland, MI, USA) containing either 50 μg estrogen (Sigma Aldrich, St. Louis,
MO, USA), 20 mg progesterone (Sigma Aldrich, St. Louis, MO, USA), or 50 μg
estrogen and 20 mg progesterone. The number four inguinal mammary glands
were removed at day zero (untreated) and day 14, fixed in 10% neutral buffered
formalin, and analyzed for ductal outgrowth by whole mount analysis.
IGF-1 serum analysis
Blood was collected retro-orbitally from anesthetized (Isoflurane) 8 week
WT, p53+/−, and p53+/m virgin mice using heparinized capillary tubes (Fisher
Scientific, Pittsburgh, PA, USA) and serum was collected by centrifugation.
IGF-1 serum levels were analyzed by an enzyme-immuno-assay kit (Immuno-
diagnostic Systems, Ltd., Boldon Business Park, Bolden, Tyne and Wear, NE,
USA) according to the manufacturer's instructions.
Western blotting
Mammary gland extracts were prepared from 8 week virgin mice or 5 week
WT and p53+/m virgin mice untreated or treated once with 100 μl of 0.25 μg/μl
LR3-IGF-1 recombinant analog (Sigma Aldrich, St. Louis, MO, USA) in 0.9%
saline+10 mg/ml BSA. Tissue was harvested 1 h post treatment. Mammary
gland extracts were prepared by pulverizing snap-frozen tissue followed by lysisin RIPA buffer (Pierce, Rockford, IL, USA) plus a protease inhibitor cocktail
(Roche, Applied Science, Mannheim, Germany) and phosphatase inhibitors
(Pierce, Rockford, IL, USA), and cleared by centrifugation. Protein concentra-
tions were determined using the BCA protein quantification assay (Pierce,
Rockford, IL, USA). Extracts were electrophoresed on a 3–8% Tris–Acetate gel
(Invitrogen, Carlsbad, CA, USA) or 4–12% Bis–Tris gel (Invitrogen, Carlsbad,
CA, USA) and transferred to PVDF membrane (Invitrogen, Carlsbad, CA,
USA). Membranes were blocked in 5% Milk-TBS-0.1% Tween followed by
incubation with IRS-1 (Upstate Lake Placid, NY, USA), AKT (Cell Signaling,
Danvers, MA, USA), pAKT (Ser473) (Cell Signaling, Danvers, MA, USA),
IGF-1R (Santa Cruz Biotechnology, Santa Cruz, CA, USA), pIGF-1R (Tyr1135/
1136) (Cell Signaling, Danvers, MA, USA), p21 (F-5) (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), p53 (R19) (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), and Actin (Lab Vision, Freemont, CA, USA).
Peroxidase-conjugated bovine anti-rabbit (Santa Cruz Biotech, Santa Cruz,
CA, USA) and anti-mouse secondary antibodies (Santa Cruz Biotech, Santa
Cruz, CA, USA) were used at 1:2000 and signal was detected with Supersignal
West Pico Solutions (Pierce, Rockford IL, USA). Membranes were stripped and
re-probed whenever possible. Protein levels were determined by immunoblot
analysis followed by densitometric analysis (GE Molecular Dynamics Personal
Densitometer SI) utilizing ImageQuaNT software (GE Molecular Dynamics).
Treatment of mice with LR3-IGF-1
Six-week WT, p53+/−, and p53+/m virgin mice were intraperitoneally (IP)
injected twice daily with 100 μl of 0.25 μg/μl LR3-IGF-1 recombinant analog
(Sigma Aldrich, St. Louis, MO, USA) in 0.9% saline+10 mg/ml BSA for 5
days. Control mice were IP injected twice daily with sterile 0.9% saline+10 mg/
ml BSA. Mammary glands were harvested, fixed in 10% neutral buffered
formalin, and whole mounted as previously described. Examination of ductal
outgrowth was performed by assessment of whole mounts using a dissecting
microscope (Olympus SZX12).
Analysis of IGF-1 mRNA levels
Total RNA was extracted from 12 week virgin WT, p53+/−, and p53+/m
mammary glands using the RNeasy Lipid Tissue Mini Kit per the manufac-
turer's instructions (Qiagen, Valencia, CA, USA). One microgram of RNAwas
reverse transcribed using the SuperScript First Strand Synthesis System for RT
PCR (Invitrogen, Carlsbad, CA, USA). Each PCR reaction contained 1 μg of
cDNA along with IGF-1 primers IGF-1F 5′ GGA CCA GAG ACC CTT TGC
GGG G 3′ and IGF-1R 5′ AAC AGA ACT TAG GAC GAG GG 3′ or β-actinF
5′ AAC AGA ACT TAG GAC GAG GG 3′ and β-actinR 5′ GGA AAC CAG
GTTGTCAGT C 3′ and was run for 35 cycles. These primers generate a 267 bp
IGF-1 product and a 209 bp β-actin product, respectively. IGF-1 expression was
normalized to β-actin levels using KODAK Digital Science 1D Software.
Results
p53+/m mice exhibit delayed ductal morphogenesis
Mammary gland morphology was examined during develop-
mental stages 8, 12, and 24 week virgin, mid-pregnancy (day 12),
and involution (day 10) in WT, p53+/−, and p53+/m mice by
whole mount analysis. Consistent with previous reports, p53+/−
mammary glands were comparable to wild-type and no
phenotypic alterations were observed at any developmental
stages (data not shown) (Donehower et al., 1992; Jacks et al.,
1994; Purdie et al., 1994). In contrast, mammary glands from 8
week old p53+/m virgin mice show reduced ductal outgrowth,
with minimal ductal growth past the primary lymph node (Fig.
1A). To confirm this delay in ductal morphogenesis, we
examined p53+/m virgin mice at 12 and 24 weeks of age and
found that these mice also exhibit decreased ductal outgrowth
Fig. 1. Representative whole mounts of WT and p53+/m mammary glands demonstrate the effects of altered p53 dosage on ductal morphogenesis. WT and p53+/m
mammary glands at 8-, 12-, and 24-week-old virgin (A), mid-pregnancy (day 12) (B), and day 10 involution (C). All images are shown at 3.5× or 15× magnification.
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number of ducts in the p53+/m glands exhibit normal gross and
cellular morphology when examined by whole mount analysis
and by hematoxylin and eosin (H and E) staining (data not
shown). Surprisingly, by mid-pregnancy (day 12), the glands of
p53+/m mice were comparable to those of both WT and p53+/−
mice, demonstrating ductal outgrowth encompassing the entire
fat pad as well as normal formation of alveolar buds (Fig. 1B). No
morphological differences in involution (day 10) were noted
between WT, p53+/−, and p53+/m glands (Fig. 1C). Further-
more, it was observed that female p53+/m mice were capable of
nursing their pups and supporting them until weaning, suggesting
that p53+/mmammary glands are functionally analogous to wild-
type glands post-partum. This suggests that the pregnancy-
mediated increase in steroid hormones may be required to induce
ductal outgrowth in the p53+/m mammary gland.Rates of cell proliferation and apoptosis during development
The p53+/m mice were previously shown to exhibit
increased levels of p53 protein in response to irradiation in
the kidney (Tyner et al., 2002). Although p53 protein levels
were not significantly increased in the mammary glands of
p53+/m virgin mice, these glands exhibit an increase in p21
levels in response to irradiation, indicative of an increase in p53
activity (Supplementary Fig. 1). The increased p53 activity in
the p53+/m mouse suggests that the decreased ductal outgrowth
observed in these mice could be due to alterations in pro-
liferation and/or apoptosis, which are important during ductal
morphogenesis, successive cycles of pregnancy, and critical
during involution (Richert et al., 2000). An in vivo BrdU
proliferation assay was performed to determine if levels of
proliferation were altered in the p53+/m mammary gland.
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developmental stages 8 and 12 week virgin, mid-pregnancy
(day 12), and D10 involution. No proliferation was observed in
the limited number of ductal epithelial cells found in the 8 and
12 week p53+/m virgin glands; however, by mid-pregnancyFig. 2. Rates of cell proliferation and apoptosis in WT, p53+/−, and p53+/m mamm
mammary gland sections stained for BrdU incorporation at 8 week virgin and mid-pre
Rate of cell proliferation at various developmental stages presented as mean perce
Representative WT, p53+/−, and p53+/m mammary gland sections TUNEL stain
Quantitative analysis of the mean percent apoptosis (±S.E.M) in WT, p53+/−, and p5
images are shown at 20× magnification.(day 12) and during involution, the p53+/m glands exhibited
rates of cell proliferation comparable to both WT and p53+/−
glands (Figs. 2A, B). These results further suggest that preg-
nancy is required to induce epithelial cell proliferation and
ductal outgrowth in the p53+/m gland.ary glands during development. (A) Representative WT, p53+/−, and p53+/m
gnancy (day 12) stages of development. Arrows indicate BrdU labeled cells. (B)
nt of BrdU Labeling Index (±S.E.M) in a bar graph (n=3 for all groups). (C)
ed at D10 involution. Arrows indicate TUNEL stained apoptotic cells. (D)
3+/m mammary glands at various development stages (n=3 for all groups). All
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apoptosis in WT, p53+/−, and p53+/m mice during various
developmental stages. Consistent with our previous results,
limited numbers of ductal epithelial cells were observed in the
p53+/m 8 and 12 week virgin glands. Virgin glands showed
comparable low levels of apoptosis across all genotypes and no
significant increase in apoptosis was detected in these glands by
TUNEL assay (Figs. 2C, D). Moreover, we did not observe
alterations in apoptotic levels between genotypes at mid-
pregnancy (day 12) or D10 involution and no differences inFig. 3. Mammary epithelium transplants demonstrate that p53 dosage alters the syst
mammary epithelial transplants into wild-type recipient mice (transplant numbe
Representative whole mounts of WT and p53+/m mammary epithelium transplants
outgrowth of both WTand p53+/m transplants into p53+/m recipient mice. Each recip
gland and p53+/m mammary epithelium in the right gland. All images are shown atmorphology were seen at D10 involution (Figs. 1D, 2C, D).
These data demonstrate that the m allele does not increase
apoptosis in the mammary gland, so apoptosis does not play a
role in the ductal defect seen in the p53+/m virgin gland.
Mammary epithelial transplants into p53+/m recipients exhibit
reduced ductal outgrowth
The delayed ductal outgrowth observed in the virgin p53+/m
gland suggests that mammary gland stem proliferation and/oremic environment. (A) Representative whole mounts of WT and p53+/m serial
r one) demonstrate complete ductal outgrowth in p53+/m transplants. (B)
into p53+/m recipient mice 4 weeks post transplant demonstrate reduced ductal
ient mouse was transplanted with WT mammary epithelium in the left mammary
3.5× magnification.
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(Fig. 1). Therefore, we compared the replicative life span of
WT, p53+/−, and p53+/m mammary gland stem cells in vivo by
performing serial mammary epithelium transplants into wild-
type recipient mice. The p53+/m transplants exhibited a slightly
reduced regenerative capacity compared to their WT counter-
parts, suggesting that cell autonomous effects of augmented p53
activity in the p53+/m mammary stem cells may have a
marginal effect on stem cell regeneration (Supplementary Table
1). Interestingly, p53+/m transplants were capable of growing to
fill the entire mammary fat pad by 8 weeks post transplant,
suggesting a systemic effect on mammary gland development in
the p53+/m mice (Fig. 3A).
The complete ductal outgrowth observed in the serial
transplantation of p53+/m epithelium into WT recipients, in
contrast to the limited ductal outgrowth seen in virgin p53+/m
glands, suggests that systemic or stromal alterations in the
p53+/m mice may play a major role in the p53+/m mammary
defect. The mammary stroma has been reported to play an
important role in regulating development and ductal morpho-
genesis in the mammary gland (Walden et al., 1998). Prolifera-
tion signals mediated through epithelial–stromal crosstalk such
as IGF-1, estrogen, and progesterone are critical for normal
development to occur (Ruan and Kleinberg, 1999; Ruan et al.,
2005). To determine if systemic or stromal alterations were
affecting ductal outgrowth in the p53+/m mice, mammary
epithelial transplants were performed with p53+/m recipient
mice. Mammary glands from WT or p53+/m virgin recipient
mice were cleared and transplanted with 8 week virgin WT
donor epithelium in the left gland and 8 week virgin p53+/m
donor epithelium in the right gland to allow for a comparison of
outgrowth. Whole mount analysis of the transplanted glands
revealed that the majority of WT and p53+/m transplants into
WT recipient mice showed robust ductal outgrowth, with all
outgrowth filling greater than 50% of the fat pad by 4 weeks post
transplant (Fig. 3B, Table 1). However, it was noted that fewer
p53+/m transplants demonstrated outgrowth compared to WT
transplants (Table 1). Interestingly, transplantation of either WTTable 1
Mammary epithelial transplants of WT and p53+/m epithelium into WT and
p53+/m recipient mice




p53+/+ p53+/+ 12/14 a 80±6 b
p53+/+ p53+/m 8/14 73±11 c
p53+/m p53+/+ 7/12 19±6 d
p53+/m p53+/m 6/12 6±2 e, f
a Proportion of outgrowths observed in recipient mice. Each recipient was
transplanted with wild-type epithelium in the left gland and p53+/m epithelium
in the right gland. Glands were harvested 4 weeks post-transplant and examined
for outgrowth by whole mount analysis. n=12–14 recipients, n=2 donors per
genotype.
b Values represent the mean percentage of ductal outgrowth ±S.E.M.
c pb0.6 compared to WT donor transplanted into WT recipient.
d pb2.88×10−6 compared to WT donor transplanted into WT recipient.
e pb0.0002 compared to +/m donor transplanted into WT recipient.
f pb0.06 compared to WT donor transplanted into +/m recipient.or p53+/m mammary epithelium into p53+/m recipient mice
exhibited significantly reduced ductal outgrowth, with a mean
percentage of fat pad filled of less than 20% in the majority of
WT transplants and only 6% ductal outgrowth in the p53+/m
transplants (Fig. 3B, Table 1). In addition, fewerWTand p53+/m
transplants into p53+/m recipients demonstrated outgrowth
(Table 1). These data suggest that the systemic increase in p53
activity and/or other systemic alterations in the p53+/m mice
contribute to the developmental delay observed in the p53+/m
mammary gland.
Steroid hormone treatment of p53+/m mice rescues mammary
gland development
Examination of p53+/m whole mounts during development
revealed that by mid-pregnancy (day 12), the p53+/m mammary
gland exhibited complete ductal outgrowth with normal
development of alveolar structures comparable to WT glands
(Fig. 1B). These results suggest that increased levels of steroid
hormones during pregnancy may be required to allow ductal
outgrowth in the presence of increased p53 levels. To determine
whether hormonal treatment is capable of stimulating mammary
gland development in virgin p53+/m mice, mice were treated
with estrogen, progesterone, or a combination of estrogen and
progesterone for 14 days. Whole mount examination of
mammary glands demonstrates that treatment with estrogen
alone, progesterone alone, or estrogen and progesterone in
combination rescues the ductal defect in virgin p53+/m mice,
stimulating ductal outgrowth past the primary lymph node (Fig.
4). These data confirm that alterations in hormone levels
induced by pregnancy are capable of stimulating ductal out-
growth in the p53+/m mice.
p53+/m mice exhibit decreased levels of serum IGF-1 and
attenuated IGF-1 signaling
The decreased outgrowth observed in mammary epithelium
transplants into p53+/m recipient mice, in addition to the
stimulation of ductal outgrowth by hormonal treatment,
suggests that the increased p53 activity in the p53+/m mice
leads to alterations in stromal or systemic signaling which may
play a role in the decreased ductal growth. Estrogen and
progesterone are both known to enhance IGF-1 activity during
ductal morphogenesis (Ruan et al., 2005). IGF-1, which is
produced primarily in the stroma and mediates the proliferation
signals of growth hormone in an autocrine fashion through
stroma-epithelial crosstalk, is known to play a critical role in
ductal morphogenesis (Ruan and Kleinberg, 1999). In addition,
serum IGF-1 may affect the mammary gland in an endocrine
manner (Liu and LeRoith, 1999; Ruan and Kleinberg, 1999).
Interestingly, IGF-1 null mice exhibit impaired mammary gland
development characterized by decreased numbers of terminal
end buds and ducts as well as a decrease in the percentage of fat
pad occupied by ductal outgrowth (Ruan and Kleinberg, 1999).
Since these phenotypes are comparable to those seen in the
p53+/m mammary gland and p53 itself has been shown to play
an integral role in regulating IGF-1 signaling through transcrip-
Fig. 4. Treatment of p53+/m mice with steroid hormones restores ductal outgrowth. Representative whole mounts of mammary glands from WT and p53+/m mice
untreated or treated with estrogen (E), progesterone (P), or estrogen and progesterone (E+P) in combination for 14 days (n=3–4).
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IGF-1 were examined in the p53+/m mouse. Serum levels of
IGF-1 were found to be significantly decreased (34%) in 8 week
virgin p53+/m mice when compared to WT mice of the same
age (Fig. 5A). While the decrease in circulating IGF-1 levels
may contribute to the p53+/m mammary phenotype, it has been
reported that paracrine levels of IGF-1 may play a more
important role in mammary ductal morphogenesis than cir-
culating levels of IGF-1 (Richards et al., 2004). Therefore,
RT-PCR was performed to examine in situ levels of IGF-1
mRNA in the mammary gland and levels of IGF-1 signaling
proteins were examined by Western blot analysis. p53+/m
virgin glands exhibit reduced levels of insulin-receptor substrate
1 (IRS-1), IGF-1R, pIGF-R, AKT, and pAKT proteins,
demonstrating reduced IGF-1 signaling (Fig. 5B), although no
difference was observed in levels of IGF-1 mRNA in p53+/m
virgin mammary glands when compared to WT glands
(Supplementary Fig. 2). These data suggest that decreased
IGF-1 serum levels lead to decreased IGF-1 signaling in the
p53+/m virgin mammary gland which may contribute to the
mammary phenotype.
Increased IGF-1 serum levels rescue mammary gland
development in p53+/m mice
To determine if the decrease in serum IGF-1 contributes to
the decreased ductal outgrowth, p53+/m mice were treated
twice daily with LR3-IGF-1 for 5 days. Examination of whole
mounts following LR3-IGF-1 treatment demonstrated a rescue
of ductal morphogenesis, characterized by increased ductaloutgrowth past the primary lymph node, with a significant
increase in the mean percentage of fat pad filled by ductal
outgrowth (Fig. 5C, Supplementary Fig. 3). LR3-IGF-1 treat-
ment of p53+/m mice also restored levels of IGF-1 signaling,
with levels of IRS-1, IGF-1R, pIGF-R, pAKT, and AKT
proteins comparable to wild-type post treatment (Fig. 5B).
Additionally, p53+/m mice were crossed to TTR-IGF-1/+
mice, which contain three copies of an IGF-1 transgene under
the transthyretin promoter, which allows for liver specific over-
expression of IGF-1, resulting in a 50–60% increase in serum
IGF-1 levels (Liao et al., 2006). To determine if the increased
serum IGF-1 levels in the TTR-IGF-1/+ mice could rescue the
mammary phenotype of the p53+/m mice, 8 week virgin glands
from TTR-IGF-1/+;p53+/m mice were examined by whole
mount. TTR-IGF-1/+;p53+/m virgin glands exhibit an increase
in ductal outgrowth past the primary lymph node (Fig. 5D),
suggesting that the increased serum IGF-1 levels due to the
presence of the TTR-IGF-1 transgenes is sufficient to rescue the
p53+/m mammary gland defect. These data confirm that
decreased levels of serum IGF-1 and decreased IGF-1 signaling
contribute to the p53+/m mammary phenotype.
Discussion
The data reported here demonstrate that the increased wild-
type p53 activity observed in the p53+/m mouse leads to a
defect in mammary gland ductal morphogenesis, which is
characterized by minimal ductal outgrowth beyond the primary
lymph node in virgin mice. Previous studies have reported that
p53 typically remains cytoplasmically sequestered in virgin
Fig. 5. Altered IGF-1 contributes to the mammary phenotype of the p53+/m mice. (A) Quantitative comparison of mean IGF-1 serum levels (±S.E.M) of 8 week virgin
WT, p53+/−, and p53+/m mice (n=9). ⁎pb0.003 compared to WT. (B) Western blot analysis of IRS-1, AKT, pAKT, pIGF-1R, and IGF-1R, shows decreased IGF-1
signaling in p53+/m 5 week virgin mammary glands compared to wild-type virgin mammary glands. Treatment with LR3-IGF-1 rescues the attenuation of IGF-1
signaling in p53+/m glands. Values below each lane indicate relative protein levels after normalization to actin levels. (C) Representative whole mounts of 6 week
virgin WT and p53+/m mammary glands from mice treated twice daily with LR3-IGF-1 for 5 days. Control mice were treated twice daily with 0.9% saline plus
10 mg/ml BSA (n=4). All images are shown at 3.5× magnification. (D) Representative whole mounts of 8 week virgin WT, p53+/m, TTR-IGF-1/+, and TTR-IGF-1/+;
p53+/m mammary glands (n=3–4). All images are shown at 3.5× magnification.
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quiescent virgin gland (Kuperwasser et al., 2000; Minter et al.,
2002). We have previously shown that the m allele increases
both p53 stability and activity (Tyner et al., 2002; Moore et al.,
in press). Additionally, the m allele drives nuclear localization
of p53 even in the absence of stress, which may contribute to theincreased p53 activity observed in the presence of the m allele
(Moore et al., in press). Although no significant increase in p53
protein levels was observed in the p53+/m virgin mammary
gland, there is an increase in levels of p21 in response to
irradiation, suggesting an increase in p53 activity in the p53+/m
mammary gland (Supplementary Fig. 1). An increase in p53
139C.E. Gatza et al. / Developmental Biology 313 (2008) 130–141activity could result in altered apoptotic levels. However, no
increase in apoptosis was observed at any developmental stage,
demonstrating that apoptosis does not play a role in the
mammary phenotype of the p53+/m mouse. Increases in p53
activity in other tissues in the p53+/m mice, as previously
observed in the kidney (Tyner et al., 2002), could cause
systemic effects that alter mammary gland development, such as
the observed decrease in serum IGF-1 levels. In fact, pre-
liminary data suggest that there is a reduced ratio of IGF-1/
IGFBP-3 mRNA levels in p53+/m liver (M. Pollak, unpub-
lished data).
The ability of p53+/m serial mammary epithelial transplants
to exhibit complete ductal outgrowth in a WT fat pad suggested
that systemic or stromal alterations in the p53+/m mice, such as
loss of IGF-1 signaling, contribute to the phenotype. In fact,
p53+/m mice exhibit a reduction in IGF-1 serum levels that may
contribute to the decreased proliferation observed in the p53+/m
virgin gland. This suggests that p53 may be able to directly or
indirectly regulate IGF-1 levels, although the mechanism re-
mains unknown at this time. Interestingly, two progeroid mouse
models, the DNA repair deficient XPF-ERCC1−/− mouse and
the Csbm/m/Xpa−/− mouse, exhibit a reduced life span and
chronic genotoxic stress which leads to suppression of the
GH/IGF-1 somatotroph axis (Niedernhofer et al., 2006; van der
Pluijm et al., 2006). It is possible that the increased p53 activity
in the p53+/m mice may potentially replicate some aspects of
the chronic genotoxic stress observed in these mice, as p53 is
directly activated by genotoxic stress. The increased p53
activity in the p53+/m mice could induce a chronic augmented
stress response, which may lead to the downregulation of the
IGF-1 somatotrophic axis.
It was previously reported that paracrine levels of IGF-1 may
play a more important role in mammary ductal morphogenesis
than circulating levels of IGF-1 (Richards et al., 2004).
However, the rescue of the p53+/m mammary phenotype by
systemic treatment with LR3-IGF-1 and by crossing to the
TTR-IGF-1/+ mice suggests that serum levels of IGF-1 sig-
nificantly contribute to mammary gland development. Although
RT-PCR analysis showed no alterations in IGF-1 mRNA levels
in the p53+/m mammary gland itself, these glands exhibit a
decrease in levels of IGF-1 signaling proteins, including the
IGF-1R, a p53 target gene. p53 is known to transcriptionally
repress expression of the IGF-1R and transcriptionally activate
expression of IGF-1 signaling inhibitors IGF-BP3 and PTEN,
demonstrating a direct role in p53-mediated regulation of the
IGF-1 pathway (Buckbinder et al., 1995; Stambolic et al., 2001;
Werner et al., 1996). In fact, disruption of the IGF-1R gene has
been shown to reduce levels of proliferation in terminal end
buds (Bonnette and Hadsell, 2001). These data suggest that the
increased p53 activity in the p53+/m mouse attenuates IGF-1
signaling.
Strikingly, the p53+/m mice are also highly tumor resistant,
which may be due in part to reduced levels of circulating IGF-1,
as an increase in IGF-1 and IGF-1R levels has been shown to
correlate with an increased risk of tumor development
(Hankinson et al., 1998). In contrast to the p53+/m model,
some of the premature aging mouse models which have beenshown to exhibit increased IGF-1 levels also display increased
incidence of tumorigenesis (Shukla et al., 2006; Xu et al., 2001).
Surprisingly, we saw a complete rescue of the p53+/m
mammary gland phenotype with the induction of pregnancy.
This rescue may be due to increased levels of estrogen and
progesterone which are known to cause secondary changes in
growth factor expression (Sternlicht et al., 2006). Interestingly,
there is evidence that pregnancy can upregulate IGF signaling
(Bonnette and Hadsell, 2001), suggesting that pregnancy may
compensate for the reduction in circulating IGF-1 levels and
decreased IGF-1 signaling observed in the p53+/m mice. In fact,
both progesterone and estrogen have been shown to synergize
with and enhance IGF-1-mediated ductal morphogenesis (Ruan
et al., 2005). Supporting this, our data demonstrate that treat-
ment with estrogen, progesterone, estrogen plus progesterone,
or LR3-IGF-1 stimulates ductal outgrowth in the p53+/m gland.
While we cannot rule out a p53-mediated reduction in estrogen
or progesterone, we observed no alterations in fecundity or
fertility in p53+/m mice, suggesting that alterations in estrogen
and/or progesterone do not contribute to the mammary pheno-
types. These data suggest that p53-mediated regulation of the
IGF-1 signaling pathway may contribute to mammary gland
development and support a model in which pregnancy-induced
proliferation signals compensate for the increased p53 activity
in the p53+/m mouse by stimulating or synergizing with IGF-1
signaling.
The decreased ductal outgrowth observed in transplantation
of wild-type and p53+/m mammary epithelium into p53+/m
recipients suggests that serum and/or stromal factors may also
play a major role in the extrinsic regulation of mammary stem
cell proliferation (Fig. 3B, Table 1). One of these extrinsic
factors is likely to be IGF-1, as there is growing evidence that
multiple stem cell types are functionally stimulated by IGF-1
(Bendall et al., 2007; Musaro et al., 2004). Intrinsic cell auto-
nomous effects of enhanced p53 in the mammary gland stem
cells may have only a minor role, as p53+/m mammary gland
stem cells exhibited a marginal reduction in serial transplant-
ation capacity compared to their WT counterparts (Supple-
mentary Table 1). However, additional studies will be required
to further clarify the role of p53 in regulation of the mammary
gland stem cell.
The data presented here suggest that increased p53 activity
can dramatically affect mammary gland development, in part
through regulation of IGF-1 signaling. The increased p53
activity present in p53+/m mice during mammary gland ductal
morphogenesis contributes to decreased proliferation in virgin
glands, decreased levels of serum IGF-1, and decreased IGF-1
signaling in p53+/m virgin glands. However, other effects of
enhanced p53 on estrogen and progesterone receptor signaling
could also be playing an important role in this model.
Collectively it is believed that these effects of increased p53
activity lead to the decreased ductal outgrowth observed in the
p53+/m virgin glands. Our work solidifies the link between p53
and hormonal regulation, demonstrating that hormonal stimula-
tion is able to overcome the proliferative block induced by
increased p53 activity. These data suggest that the regulation of
p53 activity is important for mammary gland development.
140 C.E. Gatza et al. / Developmental Biology 313 (2008) 130–141However, further work is needed to fully elucidate the effects of
altering p53 levels.
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